Sorrento Therapeutics Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Sorrento Therapeutics's estimated annual revenue is currently $21.2M per year.(i)
  • Sorrento Therapeutics received $150.0M in venture funding in November 2018.
  • Sorrento Therapeutics's estimated revenue per employee is $85,802
  • Sorrento Therapeutics's total funding is $264.4M.

Employee Data

  • Sorrento Therapeutics has 247 Employees.(i)
  • Sorrento Therapeutics grew their employee count by -49% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Sorrento Therapeutics News

2022-04-20 - $17.83 Million in Sales Expected for Sorrento Therapeutics ...

Sorrento Therapeutics, Inc, a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory,...

2022-04-19 - Scilex Holding Company, a majority-owned subsidiary of ...

About Sorrento Therapeutics , Inc. Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat...

2022-04-19 - Sorrento Announces FDA Authorization to Proceed with ...

Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Sorrento Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-10-31$34.6MUndisclosedAegis Capital CorpArticle
2014-05-15$25.0MUndisclosedAegis Capital CorpArticle
2016-04-12$150.0MUndisclosedAlly Bridge GroupArticle
2016-05-03$10.0MUndisclosedYuhan CorporationArticle
2016-11-29$75.0MUndisclosedHercules Capital, Inc.Article
2017-04-20$43.5MUndisclosedCantor Fitzgerald & CoArticle
2018-11-09$150.0MUndisclosedOaktree Capital ManagementArticle